Iovance Biotherapeutics, Inc.

Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Iovance Biotherapeutics, Inc. |
Ticker: | Ticker: IOVA |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ:IOVA). The investigation concerns whether Iovance and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On May 8, 2025, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter’s $73.7 million. The Company also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million-$475 million to $250 million-$300 million, a reduction of over 40% at the midpoint. The Company stated it was “revising full-year 2025 revenue guidance to reflect recent launch dynamics” of the Company’s T cell immunotherapy, Amtagvi (lifileucel). Amtagvi was commercially launched in the U.S. in the first half of 2024. On this news, the price of Iovance shares declined by $1.42 per share, or approximately 44%, from $3.17 per share on May 8, 2025, to close at $1.75 on May 9, 2025.
On May 8, 2025, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter’s $73.7 million. The Company also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million-$475 million to $250 million-$300 million, a reduction of over 40% at the midpoint. The Company stated it was “revising full-year 2025 revenue guidance to reflect recent launch dynamics” of the Company’s T cell immunotherapy, Amtagvi (lifileucel). Amtagvi was commercially launched in the U.S. in the first half of 2024. On this news, the price of Iovance shares declined by $1.42 per share, or approximately 44%, from $3.17 per share on May 8, 2025, to close at $1.75 on May 9, 2025.